Skip to main content
OpenTrials
Completed

NCT Number: NCT04739709

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery

This Phase 3 study will evaluate APP13007 in comparison to the matching vehicle placebo in a randomized, parallel-group, double-masked fashion. The subjects will have undergone routine cataract surgery on Day 0 of the study and will be assessed the next day (Post-operative Day 1; POD1) after uncomplicated surgery for eligibility for randomization to study treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ocular Inflammation and Pain Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Centro Oftalmologico Metropolitano, San Juan, Puerto Rico

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients 18 years of age or older expected to undergo unilateral uncomplicated cataract extraction via phacoemulsification and posterior chamber intraocular lens implantation in one eye.
  • Have a pin-hole corrected visual acuity without other correction of ≤ 1.3 logarithm of the minimum angle of resolution (logMAR) in the study eye to be operated and contralateral eye as measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart at Visit 1.
  • Willing and able to comply with study requirements and visit schedule.
  • Provide signed and dated informed consent.

Exclusion criteria

  • Have a known sensitivity or allergy to clobetasol propionate, corticosteroids, or any of the study medication's components including benzalkonium chloride and soybean lecithin or any routine medication required during cataract surgery or for the conduct of study procedures
  • Have an ACC count > 0 or any evidence of intraocular inflammation (e.g., flare) in either eye at the Screening visit
  • Have a Grade > 0 on the Ocular Pain Assessment in either eye at the Screening visit

Note: Other inclusion/exclusion criteria apply.

Treatment and study plan

APP13007, 0.05%

Drug

APP13007 eye drop, 0.05%

Matching Vehicle Placebo for APP13007, 0.05%

Drug

Matching vehicle placebo eye drop

Primary outcomes

  1. Participants With ACC Count = 0 at All Visits From Postoperative Day 8 Through Postoperative Day 15 Without Rescue Medication

    Time frame: Postoperative Day 8 and Postoperative Day 15

    The number of cells in the anterior chamber of the eye are counted using slit-lamp biomicroscopy at each study visit and the results are reported as number of cells in a 1mm x 1mm area.

  2. Participants With Ocular Pain Grade = 0 at All Visits From Postoperative Day 4 Through Postoperative Day 15 Without Rescue Medication

    Time frame: Postoperative Day 4, Postoperative Day 8 and Postoperative Day 15

    Ocular pain is measured in each eye using a subject-reported five-point (0-4) ocular pain grade scale (0 = no pain; 1 = minimal; 2 = mild; 3 = moderate; 4 = severe pain).

  3. Participants With Treatment-emergent Adverse Events (AEs)

    Time frame: From First dose to Postoperative Day 22

    Number of participants with ocular and systemic treatment-emergent AEs.

Secondary outcomes

  1. Participants With Anterior Chamber Cell Grade = 0 at POD8 Without Rescue Medication

    Time frame: Postoperative Day 8

    The number of cells in the anterior chamber of the eye are counted using slit-lamp biomicroscopy at each study visit and the results are reported as number of cells in a 1mm x 1mm area. ACC Grade 0 = 0 cells, ACC grade 1 = 1-5 cells, ACC grade 2 = 6-15 cells, ACC grade 3 = 16-30 cells, ACC grade 4 = >30 cells

  2. Participants With Anterior Chamber Cell Grade = 0 at POD15 Without Rescue Medication

    Time frame: Postoperative Day 15

    The number of cells in the anterior chamber of the eye are counted using slit-lamp biomicroscopy at each study visit and the results are reported as number of cells in a 1mm x 1mm area. ACC Grade 0 = 0 cells, ACC grade 1 = 1-5 cells, ACC grade 2 = 6-15 cells, ACC grade 3 = 16-30 cells, ACC grade 4 = >30 cells

  3. Participants With Ocular Pain Grade = 0 at POD4 Without Rescue Medication

    Time frame: Postoperative Day 4

    Ocular pain is measured in each eye using a subject-reported five-point (0-4) ocular pain grade scale (0 = no pain; 4 = severe pain).

  4. Participants With Ocular Pain Grade = 0 at POD8 Without Rescue Medication

    Time frame: Postoperative Day 8

    Ocular pain is measured in each eye using a subject-reported five-point (0-4) ocular pain grade scale (0 = no pain; 4 = severe pain).

  5. Participants With Ocular Pain Grade = 0 at POD15 Without Rescue Medication

    Time frame: Postoperative Day 15

    Ocular pain is measured in each eye using a subject-reported five-point (0-4) ocular pain grade scale (0 = no pain; 4 = severe pain).

  6. Participants With Anterior Chamber Flare (ACF) = 0 at POD4 Without Rescue Medication

    Time frame: Postoperative Day 4

    The degree of turbidity (flare) in the anterior chamber of the eye is measured using slit-lamp biomicroscopy and quantified on a five-point (0-4) anterior chamber flare grade scale (0 = none; 4 = Intense).

  7. Participants With Anterior Chamber Flare (ACF) = 0 at POD8 Without Rescue Medication

    Time frame: Postoperative Day 8

    The degree of turbidity (flare) in the anterior chamber of the eye is measured using slit-lamp biomicroscopy and quantified on a five-point (0-4) anterior chamber flare grade scale (0 = none; 4 = Intense).

  8. Participants With Anterior Chamber Flare (ACF) = 0 at POD15 Without Rescue Medication

    Time frame: Postoperative Day 15

    The degree of turbidity (flare) in the anterior chamber of the eye is measured using slit-lamp biomicroscopy and quantified on a five-point (0-4) anterior chamber flare grade scale (0 = none; 4 = Intense).

  9. Anterior Chamber Cell Grade - Change From Baseline (POD1 Prior to Dosing) to POD 15

    Time frame: Baseline and Postoperative Day 15

    The number of cells in the anterior chamber of the eye are counted using slit-lamp biomicroscopy and the results are reported as number of cells in a 1mm x 1mm area using a 5 point grading scale. ACC Grade 0 = 0 cells, ACC grade 1 = 1-5 cells, ACC grade 2 = 6-15 cells, ACC grade 3 = 16-30 cells, ACC grade 4 = >30 cells

  10. Ocular Pain Grade - Change From Baseline (POD1 Prior to Dosing) to POD 15

    Time frame: Baseline and Postoperative Day 15

    Ocular pain is measured in each eye using a subject-reported five-point (0-4) ocular pain grade scale (0 = no pain; 4 = severe pain).

  11. Anterior Chamber Flare (ACF) - Change From Baseline (POD1 Prior to Dosing) to POD 15

    Time frame: Baseline and Postoperative Day 15

    The degree of turbidity (flare) in the anterior chamber of the eye is measured using slit-lamp biomicroscopy and quantified on a five-point (0-4) anterior chamber flare grade scale (0 = none; 4 = Intense).

  12. Best Corrected Visual Acuity - Change From Baseline (POD1 Prior to Dosing) to POD4

    Time frame: Baseline and Postoperative Day 4

    The visual acuity in each eye is corrected using the pinhole method and the acuity is quantified on a logMAR (minimal angle of resolution) scale using the 'Early Treatment Diabetic Retinopathy Study' [ETDRS] charts for right and left eyes.

    A logMAR Score is calculated using the letter row on the chart and the number of incorrect letters read by the participant.

  13. Best Corrected Visual Acuity - Change From Baseline (POD1 Prior to Dosing) to POD8

    Time frame: Baseline and Postoperative Day 8

    The visual acuity in each eye is corrected using the pinhole method and the acuity is quantified on a logMAR (minimal angle of resolution) scale using the 'Early Treatment Diabetic Retinopathy Study' [ETDRS] charts for right and left eyes. A logMAR Score is calculated using the letter row on the chart and the number of incorrect letters read by the participant.

  14. Best Corrected Visual Acuity - Change From Baseline (POD1 Prior to Dosing) to POD15

    Time frame: Baseline and Postoperative Day 15

    The visual acuity in each eye is corrected using the pinhole method and the acuity is quantified on a logMAR (minimal angle of resolution) scale using the 'Early Treatment Diabetic Retinopathy Study' [ETDRS] charts for right and left eyes. A logMAR Score is calculated using the letter row on the chart and the number of incorrect letters read by the participant.

  15. Participants Using of Anti-inflammatory 'Rescue' Medication Through End-of-Treatment

    Time frame: First dose to Postoperative Day 15

    Participants who do not respond to study treatment after randomization are started on anti-inflammatory medication (referred to as 'Rescue' medication). The number of subjects starting 'Rescue' medication is recorded at each study visit

Sponsors and collaborators

Lead sponsor

Formosa Pharmaceuticals, Inc.

Industry

Registry information

Official study title

A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of APP13007 for the Treatment of Inflammation and Pain After Cataract Surgery

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Feb 5, 2021
Registry last updated
Jul 20, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.